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Abstract
Background: Epithelial cell adhesion molecule EpCAM is a transmembrane glycoprotein, which is
frequently over-expressed in simple epithelia, progenitors, embryonic and tissue stem cells,
carcinoma and cancer-initiating cells. Besides functioning as a homophilic adhesion protein, EpCAM
is an oncogenic receptor that requires regulated intramembrane proteolysis for activation of its
signal transduction capacity. Upon cleavage, the extracellular domain EpEX is released as a soluble
ligand while the intracellular domain EpICD translocates into the cytoplasm and eventually into the
nucleus in combination with four-and-a-half LIM domains protein 2 (FHL2) and β-catenin, and
drives cell proliferation.
Methods: EpCAM cleavage, induction of the target genes, and transmission of proliferation signals
were investigated under varying density conditions using confocal laser scanning microscopy,
immunoblotting, cell counting, and conditional cell systems.
Results: EpCAM cleavage, induction of the target genes, and transmission of proliferation signals
were dependent on adequate cell-to-cell contact. If cell-to-cell contact was prohibited EpCAM did
not provide growth advantages. If cells were allowed to undergo contact to each other, EpCAM
transmitted proliferation signals based on signal transduction-related cleavage processes.
Accordingly, the pre-cleaved version EpICD was not dependent on cell-to-cell contact in order to
induce c-myc and cell proliferation, but necessitated nuclear translocation. For the case of contact-
inhibited cells, although cleavage of EpCAM occurred, nuclear translocation of EpICD was reduced,
as were EpCAM effects.
Conclusion: Activation of EpCAM's cleavage and oncogenic capacity is dependent on cellular
interaction (juxtacrine) to provide for initial signals of regulated intramembrane proteolysis, which
then support signalling via soluble EpEX (paracrine).
Published: 19 November 2009
BMC Cancer 2009, 9:402 doi:10.1186/1471-2407-9-402
Received: 4 June 2009
Accepted: 19 November 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/402
© 2009 Denzel et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:402 http://www.biomedcentral.com/1471-2407/9/402Background
Epithelial cell adhesion molecule EpCAM is a membrane-
bound glycoprotein involved in signalling that promotes
gene transcription and cell proliferation [1-3]. The high-
level over-expression of EpCAM in a plethora of carcino-
mas [4] led to the use of it as a marker with prognostic
quality and as a target for therapeutic strategies [5-7].
Most-recent findings revealed the necessity for regulated
intramembrane proteolysis (RIP) for the induction of
EpCAM-related signal transduction, which initiates at the
plasma membrane [8,9]. EpCAM becomes proteolytically
activated via cleavage by TACE (tumour necrosis-factor α
converting enzyme) and a gamma-secretase complex
comprising presenilin 2 (PS2) [8]. After RIP, the intracel-
lular domain of EpCAM (EpICD) is released in the cyto-
plasm and shuttles into the cell nucleus in a complex with
the scaffold protein FHL2 (four and a half lim domain
protein 2) and β-catenin. Thereupon, EpICD contacts
members of the TCF/Lef family of transcription factors,
binds DNA at Lef consensus sites, and induces transcrip-
tion of target genes, including c-myc, cyclins, and genes
related to proliferation [2,3,8]. Expression of EpCAM in
murine and human embryonic stem (ES) cells revealed
essential to the maintenance of the pluripotent and prolif-
erative phenotype in vitro. SiRNA-mediated inhibition of
mEpCAM expression in ES cells in the presence of factors
necessary for a de-differentiated phenotype induced dif-
ferentiation, reduced proliferation, and diminished
expression levels of classical ES cell markers such as Oct3/
4 and c-Myc [10,11]. Owing to its mode of action and
capacities, EpCAM was termed a "surface-to-nucleus missile"
[9] that is involved cancer and stem cells' signalling [12].
Both, full-length EpCAM but also EpICD, which is com-
posed of twenty-six amino acids only, rendered HEK293
cells tumourigenic in vivo and yielded large tumours with
high efficiency after xenotransplantation in SCID mice.
Likewise, EpICD alone sufficed to substitute for the defi-
ciency to express EpCAM in vitro and supported prolifera-
tive signals in the absence of the remaining domains of
EpCAM [8]. It is further important to note that the over-
expression of EpCAM is part of the signature of cancer-ini-
tiating cells at least in human colon, breast, and pancreas
carcinomas [13-15]. Thus, the aptitude of EpCAM to reg-
ulate gene transcription alongside with the Wnt pathway
and its strong oncogenic potential pinpoint an important
role in cancer, eventually related to the origin of malig-
nancies, i.e. cancer-initiating cells.
It is however still not entirely understood how EpCAM
cleavage and the subsequent signalling cascades are trig-
gered. First indication for a potential mechanism came
from stainings of cell agglomerates, where EpCAM was
essentially cleaved at areas of cell-to cell contact [8]. Addi-
tionally, it was demonstrated that ectodomain shedding
resulted in the formation of soluble EpEX, which is instru-
mental as a ligand in EpCAM signalling. Treatment of
EpCAM-positive cells with a recombinant version of EpEX
(rEpEX) induced EpCAM cleavage, suggesting that after an
initial releasing trigger (i.e. in a juxtacrine fashion), solu-
ble EpEX might provide cells with a paracrine signal, as
was shown for L1, EGF-R, TNF-R, and others [16-19].
We assessed the dependency of EpCAM cleavage, signal-
ling, and proliferation for cell-to-cell contacts. EpCAM
cleavage and subsequent proliferative signals were
observed only in cells grown at sufficient initial density to
allow for cell-to-cell contact at the onset of the experi-
ment. Oppositely, cells expressing the cleaved intracellu-
lar domain EpICD instead of full-length EpCAM were
independent of contacts to neighbouring cells for proper
proliferation. Thus, cell-to-cell contact is one initial trigger
for RIP of EpCAM and nuclear translocation of the
released signalling moiety is mandatory for the induction
of gene transcription, and for cellular proliferation.
Methods
Antibodies, cell lines, and plasmids
α-EpEX antibody HO.3 [20], α-EpICD antibody (guinea
pig antibody raised against the intracellular domain; PSL,
Peptide Specialty Laboratories, Heidelberg, Germany),
HA-tag (Roche, Heidelberg, Germany), c-Myc, eFABP,
Cyclin A and E, ERα (F-10) (Santa Cruz, Santa Cruz, USA)
were used. For laser-scanning fluorescence microscopy,
dye-coupled Alexa antibodies (Alexa- 488, 594, and 647;
Molecular Probes, Karlsruhe, Germany) were used as sec-
ondary antibodies.
EpCAM, EpICD, and EpICD-HA cDNAs were cloned into
the eukaryotic expression vector pCAG-141 to achieve
constitutive expression. Additionally, EpICD was fused to
a mutated ligand-binding domain of the human estrogen
receptor (ERT, kind gift of Prof. Dr. Georg Bornkamm)
and cloned into pCAG141. All constructs were expressed
in human embryonic kidney cells (HEK293). Induction of
nuclear translocation of EpICD-ERT was accomplished
with 100 nM 4-hydroxytamoxifen (Sigma, Munich, Ger-
many). Stable cell clones were generated by transfection
using MATra (IBA, Göttingen, Germany) and selection
with 1 μg/ml puromycin (Sigma, Munich, Germany).
HEK293 transfectants, HCT-8 and MCF-7 wild type cells
were cultured in DMEM with 10% fetal calf serum.
Cell counting and doubling time
HEK293 transfectants were plated in 10 cm dishes at dif-
ferent densities (3 × 105 or 3 × 106 cells/dish). Cell num-
bers were assessed at different time points upon trypan
blue exclusion assay as indicated. Colon carcinoma cells
(HCT-8) and breast carcinoma cells (MCF-7) were plated
at different densities as follows: D1: 0,5 × 105 cells/well inPage 2 of 14
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3 × 105 cells/well representing 0.31 × 105 cells/cm2; D3:
20 × 105 cells/well representing 2.18 × 105 cells/cm2 and
treated similarly. Doubling times were calculated as
described [2]. In order to achieve different cell densities
with fix cell numbers, 4 × 105 and 2 × 106 cells were plated
in culture dishes with increasing areas. D14 × 105 = 0.07 ×
105 cells/cm2 and D12 × 106 = 0.14 × 105 cells/cm2; D24 × 105
= 0.42 × 105cells/cm2 and D22 × 106 = 0.35 × 105 cells/cm2;
D34 × 105 = 2 × 105 cells/cm2 and D32 × 106 = 2.08 × 105
cells/cm2.
Immunoblot and immunoprecipitation
For immunoblot analysis, all cell lines were seeded as
described for cell counting. Cells were lysed at the indi-
cated time points in 50 μl lysis buffer (1% Triton X100 in
TBS). Amounts of proteins were assessed with the BCA™
Protein Assay Kit (Pierce, Thermo Scientific, Rockford, IL,
USA). 50 μg of protein lysate were mixed with SDS-PAGE
loading buffer (25 mM TrisHCl pH7, 5% glycerin, 1%
SDS, 2% beta-mercaptoethanol, bromphenol blue). Pro-
teins were separated by SDS-PAGE, transferred onto PVDF
membranes (Millipore, Bedford, US), and detected using
specific antibodies in combination with horseradish per-
oxidase (HRP)-conjugated secondary antibodies and the
enhanced chemiluminescence (ECL) reagent (Amersham
Biosciences, Freiburg, Germany).
For immunoprecipitation, cells were lysed in PBS/1% tri-
ton X100 and protease inhibitors (Roche, Mannheim,
Germany). Precleared cell-free supernatants (100,000 g,
30 min) were incubated at 4°C overnight with protein G
beads (30 μl, Amersham Biosciences, Freiburg, Germany)
loaded with 1 μg of the EpEX-specific antibody HO.3 [20].
Protein G beads were collected by centrifugation, and the
pellets were washed five times in cold lysis buffer. Immu-
noprecipitates were eluted in SDS-PAGE loading buffer
(25 mM TrisHCl pH7, 5% glycerin, 1% SDS, 2% beta-
mercaptoethanol, bromphenol blue). Immunoprecipi-
tates were analysed by immunoblotting with EpEX-spe-
cific antibodies.
Laser scanning fluorescence microscopy
HCT-8, and MCF-7 cells and HEK293 transfectants were
analyzed with a fluorescence laser scanning system (TCS-
SP2 scanning system and DM IRB inverted microscope,
Leica, Solms, Germany). If stapled sections were recorded,
depth of section was 100-180 nm in average. For EpEX
and EpICD detection, cells were fixed according to Brock
et al. [21] and stained with specific antibodies, followed
by Hoechst 33342 labelling of nuclear DNA (Sigma,
Munich, Germany). Profiling of EpEX, EpICD, and
nuclear DNA localisation was conducted with the Leica
LCS Lite software with a minimum of 900 measurement
points per cell. Where indicated, HCT-8 cells were treated
with with 1 μg rEpEX (recombinantly expressed in yeast,
Dr. H. Lindhofer, Trion Pharma, Munich Germany)
before confocal microscopy was performed.
Results
EpCAM cleavage depends on cell-to-cell contact
HCT8 (colon) and MCF7 (breast) carcinoma cells were
seeded at 0.5 × 105 (D1 = 0,05 × 105/cm2), 3 × 105 (D2 =
0,31 × 105/cm2), and 20 × 105 (D3 = 2,18 × 105/cm2) cells
in a six well format. Under those conditions, initial cell
densities represented single cells (D1), approximately
30% confluency (D2), and up to 90% confluency (D3) for
each cell line (Figure 1A). Cell surface expression of
EpCAM was monitored for each cell density over a time
period of two days by flow cytometry with antibodies spe-
cific for the extracellular domain of EpCAM. Same cell
numbers were assessed for each sample and time point,
and EpCAM cell surface expression was given as mean flu-
orescence intensity (MFI) ratio of EpCAM versus control
staining. Highest EpCAM expression values were observed
in cells seeded at lowest densities (D1 and D2) and at the
first day of measurement (Figure 1B, C). At higher densi-
ties, expression of EpCAM epitopes recognised by the
EpEX-specific antibody decreased at the cell surface of
HCT8 and MCF7 (Figure 1B, C). This decrease was even
more pronounced over time for the case of HCT8 cells,
which had lowest EpCAM levels at the cell surface at day
3 and under D3 conditions (Figure 1B). In HCT8 cells, an
increase of EpCAM cell surface expression was seen one
day post seeding under D1-2 conditions (Figure 1B).
Measurement of EpCAM expression in MCF7 cells under
the same conditions was restricted to a two days time span
owing to the substantially bigger size of these cells as com-
pared to HCT8 cells, which precluded further culture
under those conditions. Nonetheless, significantly
decreased levels of EpEX staining in MCF7 were apparent
as early as day 1 (Figure 1C).
Regulated intramembrane proteolysis (RIP) is mandatory
for activation of EpCAM-signalling in carcinoma cells and
may represent the basis for the observed decrease of intact
EpCAM molecules at the cell surface owing to EpEX shed-
ding. Cell-free supernatants of HCT8 and MCF7 cells (400
μg each) cultured under D1, D2, and D3 conditions were
immunoprecipitated with antibodies specific for the shed
ectodomain EpEX. Detectable amounts of soluble EpEX
were observed in the culture supernatant of HCT8 and
MCF7 cells at day 1 under D2 and D3 conditions but
hardly under density condition 1 (Figure 1D, E). Amounts
of soluble EpEX were further increased at day 2 (Figure
1D, E). Inductions of EpEX secretion were measured upon
densitometry and compared amongst cells with differing
initial seeding (D2/D1 and D3/D1). Ratios were 5.8- and
20-fold for HCT8, and 7- and 23-fold for MCF7 at day 1,
respectively. Inductions were 1.8- and 3.5-fold for HCT8,Page 3 of 14
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in Figure 1D, E). In order to further control and validate
these findings, two fix cell numbers (4 × 105 and 2 × 106)
were each plated in culture dishes with increasing sizes
resulting in starting densities comparable to D1-3 for both
starting cell numbers (see Materials and Methods for
details). At the time points of assessment, supernatants
were equilibrated to the maximal volumes and served as a
source to immunoprecipitate EpEX with specific antibod-
ies. As for the case of differing cell numbers, EpEX shed-
ding increased along with rising densities and resulted in
similar n-fold inductions (Figure 1F and 1G). Hence,
EpEX amounts shed per cell increased with enhanced den-
sities.
Next, EpCAM cleavage was monitored in carcinoma cells
upon dual staining with domain-specific antibodies
against EpEX and EpICD in conjunction with distinct flu-
orescence-labelled secondary antibodies in carcinoma
cells. This allows for the visualisation of cellular re-locali-
sation of EpICD [8]. HCT8 colon carcinoma cells at the
lowest density occurred as single cells at the time point of
seeding and were characterised by a co-localisation of
EpEX and EpICD at the plasma membrane after one day
in culture, which was indicative of intact EpCAM mole-
cules (Figure 2A left panels). Substantial cleavage of
EpCAM was seen in cells present as duplets or triplets,
only. An increase of cell density resulted in cell-to-cell
contact and in obvious translocation of EpICD into the
cytoplasm and nucleus (Figure 2A middle and right pan-
els). When comparing D2 and D3, nuclear translocation
of EpICD appeared somewhat reduced and perinuclear
accumulation was enhanced under conditions of high ini-
tial cell density (compare Figure 2A lower middle and
right panels). Single cells under high-density culture con-
ditions (D2 and D3) were nonetheless characterised by
cleaved EpCAM molecules and relocalisation of EpICD
within the cytoplasm and nucleus (Figure 2A, upper mid-
dle and right panels). Induction of EpCAM cleavage at the
surface of single cells under these culture conditions
might be explained by the presence of soluble EpEX in the
supernatant of cells as early as in the D2 settings (see Fig-
ure 1D, E). Recombinant EpEX substituted for cell-to-cell
contact in order to induce EpCAM cleavage in single cells
while it had no effect on densely cultured cells (Addi-
tional File 1).
EpICD sub-cellular localisation and nuclear translocation
was assessed in a semi-quantitative fashion in HCT8 cells
for each density. Cells cultured under D1 conditions
showed a predominant membraneous localisation of
EpICD, with 86% of sections (n = 50) displaying interme-
diate to strong EpICD staining at the plasma membrane,
while only 14% of sections displayed weak staining and
none of the sections showing cells entirely devoid of
EpICD at the plasma membrane. Membrane staining
gradually decreased with increasing cell density and
resulted in cells devoid of EpICD at the plasma membrane
in 100% of sections analysed under D3 (Figure 2B). This
phenotype was likewise prominent when assessing EpICD
localisation at cell-to-cell contacts, which was completely
lost in D3 conditions (Figure 2B). Loss of membraneous
localisation was paralleled by increased appearance of
EpICD in the cell cytoplasm and nucleus when comparing
D1 with D2 and 3. However, nuclear translocation was
reduced under D3 conditions and at day 3, and displayed
a strong perinuclear staining with residual nuclear stain-
ing (Figure 2, 78% weak staining in the nucleus). Similar
results were obtained with the breast cancer cell line
MCF7 (data not shown). Semi-quantitative data were fur-
ther corroborated by a software-guided profiling of EpEX,
EpICD, and DNA in confocal sections of cells cultured
under differential densities. The profiles of EpEX and
EpICD stainings were essentially overlaying for the case of
cells culture under density D1. In contrast, EpICD locali-
sation was cytoplasmic, perinuclear, and nuclear in cells
grown under density D2 and D3 conditions. We con-
firmed an accumulation and enhancement of perinuclear
staining, and reduced nuclear localisation of EpICD
within cells kept under density D3 (Figure 3).
EpCAM cleavage is dependent on cell-to-cell contactFigure 1 (see previous page)
EpCAM cleavage is dependent on cell-to-cell contact. (A) HCT8 and MCF7 cells were seeded at three different conflu-
encies (D1-3), which resulted in single cells (D1), 20% (D2), and 80% confluency (D3). (B, C) Cell surface expression of EpEX 
was assessed in samples of D1-D3 conditions over a time period of 2-3 days. Shown are the mean fluorescence intensity ratios 
of EpEX/control with standard deviations from three independent experiments for HCT8 (B) and MCF7 cells (C). Significant 
differences are marked (* p < 0.05; ** p < 0.005). (D, E) Soluble EpEX was assessed in supernatants of HCT8 (D) and MCF7 
(E) cells in samples of D1-3 conditions. Equal amounts of protein from cell-free supernatants were immunoprecipitated (IP) 
with EpEX-specific antibodies and EpEX detected by immunoblotting with specific antibodies in combination with HRP-conju-
gated secondary antibody (marked EpEX). (F) MCF7 cells were plated at 4 × 105 (left panels) or 2 × 106 (right panels) on 
increasing areas corresponding to D1, 2, and 3. At day 1 and 2, cell-free supernatants were processed as in E. Levels of EpEX 
were assessed by image densitometry, normalised for the amount of heavy chain, and values for D1 set to one for a reference. 
EpEX levels are given n-fold of D1. Shown are representative results from three independent experiments. HC: heavy chains of 
IP antibodies. LC: light chains of IP antibodies.Page 5 of 14
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Visualisation of EpCAM cleavage dependence on cell-to-cell contactF gure 2
Visualisation of EpCAM cleavage dependence on cell-to-cell contact. (A) HCT8 cells were seeded at three different 
confluencies (D1-3), which resulted in single cells (D1), 20% (D2), and 80% confluency (D3). Thereafter, HCT8 cells were 
stained with antibodies specific for EpEX (green) and EpICD (red), and cellular DNA was stained with DAPI (blue). Merged pic-
tures are displayed in the lower right quadrant of each section. Fluorescence was recorded with a laser scanning confocal 
microscope. Shown are three representative sections of each condition. (B) EpICD localisations were assessed semi-quantita-
tively and are given as percentages of cells with no (-), weak (+), intermediate (++), and strong (+++) staining at the membrane, 
at cell-to-cell contacts, and within the nucleus.
BMC Cancer 2009, 9:402 http://www.biomedcentral.com/1471-2407/9/402Induction of EpCAM targets and proliferation
De novo or over-expression of EpCAM results in the up-
regulation of c-Myc, cyclins, and e-FABP, amongst others
[2,22,23]. Regulated intramembrane proteolysis of
EpCAM and nuclear translocation of EpCID is associated
with induction of target gene expression [3,8,12]. Regula-
tion of the target genes c-myc, cyclin A and E, and e-fabp
was assessed at the protein level and in dependency of the
initial cell density at the time point of seeding. c-Myc, cyc-
lin E and A, and e-FABP expression was induced at day
EpEX, EpICD, and DNA subcellular localisation was quantified in HCT8 cells grown under density conditions 1-3Figure 3
EpEX, EpICD, and DNA subcellular localisation was quantified in HCT8 cells grown under density conditions 
1-3. Sections with a minimum of 900 measurement points were assessed per cell using the LSC Lite software. Shown are rep-
resentative cells (right panel) and the according localisation plots of fluorescence intensity across cells.Page 7 of 14
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(D2 and D3) as compared to the lower density (D1, Figure
4). No substantial additional increase in target gene
expression was observed at day 2 for D2 and D3, while tar-
get gene induction occurred for D1 conditions at this time
point most probably owing to increased cell density (Fig-
ure 4, right panels). Levels of target gene expression in
cells cultured under density D1 conditions were set to one
in order to compare induction ratios across the differen-
tial densities (see n-fold numbers in Figure 4). A maximal
26-fold induction was observed for c-Myc in HCT8 cells
(D3/D1) at day one.
Since cleavage and target gene induction were up-regu-
lated in dependency of cell-to-cell contact, we analysed
whether these signalling processes also resulted in
changes in proliferation rates. HCT8 cells were seeded at
D1, D2, and D3 and cell numbers assessed after 24 hrs
and 48 hrs. In order to compare proliferation rates
depending on the seeding density, doubling times (td)
were calculated. Td of cells grown under high-density con-
ditions (D2 and D3) were significantly lower than those
grown at low density (D1) at day one (D1: 0,43 ± 0,06
days; D2: 0,34 ± 0,02 days; D3: 0,34 ± 0,0 days). These dif-
ferences were statistically significant: D1/D2 p = 0.04 and
D1/D3 p = 0.04. At day two, cells initially seeded at D2
still had a significantly reduced td as compared to D1 (D1:
0,49 ± 0,03 days; D2: 0,43 ± 0,012 days). However, cells
initially seeded at D3 already reached confluency and dis-
played significantly increased td (D3: 054 ± 0.006 days),
i.e. a decreased proliferation rate (Table 1). These differ-
ences were statistically significant: D1/D2 p = 0.014 and
D1/D3 p = 0.04. Thus, seeding density impacted on dou-
bling times of HCT8 cells. Cells initially seeded at densi-
ties precluding cell-to-cell contact (D1) were characterised
by initially higher td and reciprocally by lower prolifera-
tion rates.
Cleaved EpICD is functionally independent of cell density
Cell-to-cell contact was mandatory as an initial trigger to
activate EpCAM via regulated intramembrane proteolysis
(see Figure 2). Conversely, we reasoned that EpICD, when
expressed as a soluble molecule, should be independent
of cell density at initial seeding. In order to test this
hypothesis, EpCAM-negative human embryonic kidney
(HEK293) cells were stably transfected with a control vec-
tor, an EpCAM expression vector, and expression vectors
encoding for EpICD and EpICD-HA. EpICD was visual-
Induction of EpCAM target genesFig re 4
Induction of EpCAM target genes. HCT8 (A) and MCF7 (B) cells were seeded at three different confluencies (D1-3). At 
day 1 and 2 cells were lysed and the protein expression of the EpCAM target genes c-myc, cyclin E and A, and efabp was 
assessed upon immunoblotting with specific antibodies. For a control, actin expression levels were assessed in parallel. Levels 
of target genes were assessed by image densitometry, normalised for the amount of actin, and values for D1 set to one for a 
reference. Target gene levels are given n-fold of D1. Shown are representative results from three independent experiments.Page 8 of 14
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clones. Expectedly, HEK293 control cells were devoid of
EpICD, while HEK293-EpCAM cells displayed EpICD
staining at the plasma membrane and to lesser extent in
the cytoplasm (Figure 5A). HEK293-EpICD and HEK293-
EpICD-HA transfectants expressed EpICD throughout the
cells, including the cytoplasm, perinuclear areas, and the
nucleus (Figure 5A).
In these cell transfectants, the induction of c-Myc was
monitored in dependency of the initial seeding density. A
ten-fold difference in seeding density was chosen (3 × 105
and 3 × 106 in a 10 cm culture dish format). At low seed-
ing density, EpCAM expression did not influence c-Myc
expression as compared with control cells (ratio EpCAM/
control = 1.1), while EpICD and EpICD-HA expression
associated with a two-fold increase in c-Myc levels (Figure
5B left panel). In contrast, EpCAM expression induced
enhanced levels of c-Myc when cells were seeded at higher
density, which allowed for cell-to-cell contact. Under
these conditions, induction of c-Myc by EpCAM, EpICD,
and EpICD-HA was similar and superior to EpCAM-nega-
tive control cells (Figure 5B right panel; 1.9-, 2-, and 3.7-
fold, respectively).
Next, we compared the effect of EpCAM and EpICD on
cell proliferation depending on the initial cell density in
the genetic background of EpCAM-negative HEK293 cells.
As for the induction of c-Myc, EpCAM expression resulted
in increased cell numbers as compared to control trans-
fectants only under high-density conditions (Figure 5C,
right panel). EpICD and EpICD-HA remained unaffected
by cell densities in their capacity to increase cell prolifera-
tion. EpICD-positive cells steadily grew to numbers three-
fold higher than control cells at day three, independently
of the seeding density (Figure 5C, left panel). Hence,
EpICD was independent of cell-to-cell contact with
respect to its capacity to induce a proliferation phenotype
in HEK293 cells, while EpCAM requires sufficient initial
density.
Nuclear translocation is mandatory to develop EpICD 
effects
Although suggested by data available so far, an experi-
mental proof of a requirement of nuclear translocation of
EpICD in order to deploy oncogenic effects is still lacking.
We established a cellular system to test this notion in vitro.
EpICD was fused to a mutated ligand-binding domain of
the human estrogen receptor, which reacts to tamoxifen,
in order to generate EpICD-ERT. As a control the ERT moi-
ety was transfected in HEK293 cells. Both proteins were
visualised upon immunoblotting with EpICD- or ER-spe-
cific antibodies (Figure 6A). In the absence of the estrogen
analog 4-hydroxytamoxifen (4-OHT), the EpICD-ERT
fusion is retained in the cytoplasm. Upon addition of 4-
OHT to culture media, EpICD-ERT is relieved from bind-
ing to chaperones and can translocate into the nucleus
(Figure 6B). Control ERT and EpICD-ERT transfectants
were compared for their proliferation capacity by cell
counting. After four days, control ERT grown in the pres-
ence or absence of 4-OHT and EpICD-ERT cells grown in
the absence of 4-OHT did not differ in cell numbers (Fig-
ure 6C). Induction of EpICD-ERT nuclear translocation
however resulted in a mean increase of cell numbers by a
factor of two (Figure 6C), and was paralleled by 3-fold
enhanced c-Myc protein levels (Figure 6D). These effects
and values were similar to phenotypes observed upon de
novo expression of full length EpCAM in HEK293 cells
[2].
Discussion
More and more, a dual role for EpCAM becomes evident
as was long known for cadherins and proteins of the
immunoglobulin superfamily [24,25]. EpCAM is a trans-
membrane protein engaged in cell adhesion [26] and
nuclear signalling [8,9], which is instrumental in cell pro-
liferation and morphoregulation [27,28]. Generally
speaking, high expression of EpCAM associated with a
proliferative and regenerative phenotype in normal tis-
sues [29-31] with active sites of cell division, and with
cancer-initiating cells in tumours in vivo [32,33]. Eventu-
ally, EpCAM is reckoned as a potent oncogenic factor,
which is activated via regulated intramembrane proteoly-
sis [8,9] and which plays an important role in cancer and
stem cell signalling [10-12]. In this respect, the remarka-
bly short intracellular domain termed EpICD is necessary
and sufficient to deploy oncogenic effects in vitro and in
animal models of cancer [2,8].
In the present work, we have assessed the actual need for
cell-to-cell contact for the activation of EpCAM cleavage
via regulated intramembrane proteolysis. Upon variation
of cell densities, it became clear that cell-to-cell contact
Table 1: Doubling times of HCT8 colon carcinoma cells 
depending on initial seeding density.
Doubling time (td) in days
Cell number td 24 hrs td 48 hrs
0.5 × 105 0,43 ± 0,06 0,49 ± 0,03
3 × 105 0,34 ± 0,02* 0,43 ± 0,012*
20 × 105 0,34 ± 0,0* 0,54 ± 0,006*
Given are mean doubling times from three independent experiments 
with standard deviations.
* Significance relates to td at lowest seeding density (p < 0.05).Page 9 of 14
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BMC Cancer 2009, 9:402 http://www.biomedcentral.com/1471-2407/9/402was involved in the initial activation of EpCAM signal
transduction by cleavage. If cellular contact was allowed,
then cleavage proceeded, was sufficient to generate solu-
ble EpEX, to release EpICD from its membrane-associated
localisation, and to induce target genes. Soluble EpEX
conferred cleavage to single cells in the culture under these
conditions. This type of initial juxtacrine activation fol-
lowing cell-to-cell contact may allow for a restricted radius
of strong effects and may achieve fine patterns of cellular
cross-talk [16]. The ability to create a soluble ligand in the
form of shed EpEX provides even more flexibility. Upon
initial local contact, cells generate a means for long range
paracrine signalling including a gradient of activation.
Interestingly, EpCAM interacts with CD44 [34], itself a
transmembrane protein that becomes cleaved, which
hence appears as a common theme of receptor co-activa-
tion that is apparently governed by tetraspanins and asso-
ciated proteins [35-37]. The assembly and disruption of
such complexes is yet another level of regulation of signal-
ling, which in vivo might be affected by cell-to-cell con-
tacts. Certainly, the differential localisation of EpCAM in
normal tissue (basolateral) versus carcinomas (homoge-
nous distribution at the membrane) will further influence
EpCAM interactions and activation.
Cleavage and nuclear translocation of EpCAM is associ-
ated with an induction of target genes [2,23] and with
reduced doubling times given the fact that cells were not
contact inhibited. Thus, EpCAM interactions may allow a
sensing of the presence of cognate cells to trigger prolifer-
ation via EpCAM cleavage and nuclear translocation of
EpICD such as in condition D2. This would rather mimic
the state of micrometastasis and of normal stem/progeni-
tor cells, e.g. when repopulating injured organs. Notably,
the regeneration of damaged liver and kidney were con-
ducted by progenitor cells, which re-expressed EpCAM to
high levels. Upon differentiation to hepatocytes and com-
pletion of organ regeneration, EpCAM expression is lost
again [31,38,39]. In case neighbouring cells are missing,
like it is e.g. the case for disseminated tumour cells, cells
might decrease levels of EpCAM activation, receive less
proliferation signals, and might rest in a state of quies-
cence (condition D1). For the case of contact inhibition of
cell proliferation, although cleavage of EpCAM occurred
to high extent, nuclear translocation was reduced and
EpICD accumulated as peri-nuclear speckles besides
nuclear speckles. Nonetheless, these remaining levels of
nuclear EpICD were instrumental for the rapid induction
of target genes, which reached a plateau at day two of
assessment. For the case of MCF-7 cells, which are bigger
than HCT-8, a reduction of the target gene c-Myc was
observed under D3 conditions already at day 2 and might
hence be anticipated for HCT-8 at later time points. These
imaging results were paralleled by corroborative cells
numbers. Cells grown under high density conditions only
displayed low doubling-times at day one, with a sharp
increase of doubling times at day two. Inhibitory effects
impacting on EpICD nuclear translocation might further
account for differences in localisation as observed in vivo
in normal colonic mucosa and colon carcinomas [8].
The molecular basis for this partial reduction of EpICD
nuclear translocation and its potential implication in the
regulation of EpCAM effects are totally unclear and
deserve further research. Most probably, effects of EpCAM
on proliferation are overcome and dampened by mecha-
nisms of contact inhibition, which might even actively
impair on EpICD nuclear translocation, e.g. via cytoplas-
mic inhibitors which retain EpICD. This means of regula-
tion of EpCAM effects at the level of subcellular
localisation was further underscored by experiments using
conditional systems in vitro. For the first time, targeted
translocation of EpICD demonstrated the necessity of
nuclear localisation in order to deploy regulatory effects
on the expression of c-Myc and on cell proliferation.
In summary, EpCAM becomes cleaved upon cell-to-cell
contact in a juxtacrine manner and additionally fosters
signalling in a paracrine fashion using soluble EpEX.
EpICD provides target gene and proliferation induction independently of cell-to-cell contactFigure 5 (see previous page)
EpICD provides target gene and proliferation induction independently of cell-to-cell contact. (A) Human embry-
onic kidney HEK293 cells were stably transfected with empty vector, EpCAM, EpICD, or EpICD-HA expression vectors. 
EpICD was stained with specific antibodies (red) and nuclear DNA was stained with DAPI (blue). Shown are representative 
sections recorded with a laser scanning confocal microscope. (B) The indicated HEK293 transfectants were seeded at initial 
densities of 3 × 105 and 3 × 106 cells and c-Myc expression was assessed upon immunoblotting with specific antibodies. For a 
control, actin expression levels were assessed in parallel. Shown are representative results from three independent experi-
ments. (C) The indicated HEK293 transfectants were seeded at initial densities of 3 × 105 and 3 × 106 cells. Cell numbers were 
assessed at day three and seven after seeding. Levels of c-Myc expression were assessed by image densitometry, normalised for 
the amount of actin, and values for D1 set to one for a reference. Target gene levels are given n-fold of D1. Shown are the 
mean cell numbers with standard deviation from three independent experiments. Significant differences are marked (* p < 0.05; 
** p < 0.005).Page 11 of 14
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EpICD nuclear translocation is mandatory for functionFigure 6
EpICD nuclear translocation is mandatory for function. (A) HEK293 cells were stably transfected with ERT or EpICD-
ERT expression plasmids. Expression of ERT and EpICD-ERT was assessed upon immunoblotting with ER- and EpICD-specific 
antibodies in combination with HRP-conjugated secondary antibody. Shown are representative results from three independent 
experiments. (B) HEK293 EpICD-ERT were treated with 4-hydroxytamoxifen (4-OHT, 100 nM) or diluent only (w/o 4-OHT) 
for 1 hr. EpICD was stained with specific antibodies (red) and nuclear DNA was visualised with DAPI (blue). Sections were 
recorded with a laser scanning confocal microscope. Shown are representative images from three independent experiments 
with multiple sections each. (C) HEK293ERT and HEK293EpICD-ERT cells were plated (3 × 105/plate) and cultured in the pres-
ence or absence of 4-OHT for three days. Cell numbers were assessed upon trypan blue counting and mean numbers with 
standard deviations from two independent experiments are given (* p < 0.05). (D) HEK293EpICD-ERT cells were treated with 
4-hydroxytamoxifen (4-OHT, 100 nM) or diluent only (w/o 4-OHT) and c-Myc expression was assessed upon immunoblotting 
with specific antibodies and HRP-conjugated secondary antibodies. For a control, actin expression levels were assessed in par-
allel. n-fold induction of c-Myc was assessed upon densitometry and is given as the ratio of tamoxifen- versus control-treated 
cells. Shown are representative results from two independent experiments.
BMC Cancer 2009, 9:402 http://www.biomedcentral.com/1471-2407/9/402Conclusion
Activation of EpCAM's cleavage and oncogenic capacity is
dependent on cellular interaction (juxtacrine) to provide
for initial signals of regulated intramembrane proteolysis,
which then support signalling via soluble EpEX (para-
crine).
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